[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvvj-Ukb1hvrvNhn242YN97unSsfS4WUeJVRsOw2e6p8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"NSABP Foundation Inc",[4],66,false,3,29,91541,4,8,[14,17,20,22,24,27,29,31],{"name":15,"count":16},"Breast Cancer",35,{"name":18,"count":19},"Colorectal Cancer",14,{"name":21,"count":11},"Metastatic Colorectal Cancer",{"name":23,"count":8},"Fatigue",{"name":25,"count":26},"HER2-negative Breast Cancer",2,{"name":28,"count":26},"Breast Neoplasms",{"name":30,"count":26},"Metastatic Cancer",{"name":32,"count":26},"Rectal Cancer",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03281954","Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","2024-12-31","Atezolizumab",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07058012","A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)","2029-04-17","Cemiplimab",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,77,102,120,138,358,413,464,519,585,646,681,724,750,799,825,854,876,898,926,944,962,980,1005,1023,1041,1059,1077,1095,1113,1131,1149,1175,1199,1217,1235,1253,1271,1289,1307,1330,1348,1366,1389,1445,1471,1493,1527,1549,1577,1595,1613,1631,1649,1671,1689,1707,1725,1749,1778,1796,1814,1832,1856,1874,1899,1917,1935,1953,2004,2046,2068,2103,2125,2151,2173,2191,2209,2227,2253],{"intervention":38,"totalTrials":53,"cells":54},1,{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":62,"PHASE4":73,"NA":75},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[],{"trials":63,"activeCount":53,"soonestReadout":37},[64],{"nctId":35,"briefTitle":36,"status":65,"phases":66,"primaryCompletion":37,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":72},"ACTIVE_NOT_RECRUITING",[48],"2027-11-30","2017-12-19",1550,[71],"Triple Negative Breast Cancer",[38],{"trials":74,"activeCount":57},[],{"trials":76,"activeCount":57},[],{"intervention":43,"totalTrials":53,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":96,"PHASE4":98,"NA":100},{"trials":80,"activeCount":57},[],{"trials":82,"activeCount":57},[],{"trials":84,"activeCount":53,"soonestReadout":42},[85],{"nctId":40,"briefTitle":41,"status":86,"phases":87,"primaryCompletion":42,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"RECRUITING",[47],"2029-06-01","2026-04-17",79,[92],"Colo-rectal Cancer",[43,94,95],"cemiplimab plus fianlimab","cemiplimab + REGN7075",{"trials":97,"activeCount":57},[],{"trials":99,"activeCount":57},[],{"trials":101,"activeCount":57},[],{"intervention":94,"totalTrials":53,"cells":103},{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":114,"PHASE4":116,"NA":118},{"trials":105,"activeCount":57},[],{"trials":107,"activeCount":57},[],{"trials":109,"activeCount":53,"soonestReadout":42},[110],{"nctId":40,"briefTitle":41,"status":86,"phases":111,"primaryCompletion":42,"completion":88,"start":89,"enrollment":90,"conditions":112,"interventions":113},[47],[92],[43,94,95],{"trials":115,"activeCount":57},[],{"trials":117,"activeCount":57},[],{"trials":119,"activeCount":57},[],{"intervention":95,"totalTrials":53,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":123,"activeCount":57},[],{"trials":125,"activeCount":57},[],{"trials":127,"activeCount":53,"soonestReadout":42},[128],{"nctId":40,"briefTitle":41,"status":86,"phases":129,"primaryCompletion":42,"completion":88,"start":89,"enrollment":90,"conditions":130,"interventions":131},[47],[92],[43,94,95],{"trials":133,"activeCount":57},[],{"trials":135,"activeCount":57},[],{"trials":137,"activeCount":57},[],{"intervention":139,"totalTrials":140,"cells":141},"Cyclophosphamide",17,{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":223,"PHASE4":354,"NA":356},{"trials":143,"activeCount":57},[],{"trials":145,"activeCount":57},[],{"trials":147,"activeCount":57},[148,162,176,189,201,212],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT03412643","Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling","UNKNOWN",[47],"2023-10-30","2018-05-14",64,[25],[158,139,159,160,161],"Doxorubicin","Weekly Paclitaxel","Trastuzumab","Pertuzumab",{"nctId":163,"briefTitle":164,"status":165,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT00003352","Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer","COMPLETED",[47],"2000-09","2002-12","1998-06",89,[15],[173,174,175],"cyclophosphamide","Taxotere","Adriamycin",{"nctId":177,"briefTitle":178,"status":165,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT00365417","Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer",[47],"2008-02","2009-11","2006-08",45,[15],[186,158,139,187,188],"Bevacizumab","Capecitabine","Docetaxel",{"nctId":190,"briefTitle":191,"status":165,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NCT01705691","Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A\u002FC in Women With Locally Advanced HER2-Negative Breast Cancer",[47],"2014-03","2015-10","2012-09",50,[15,25],[199,200,158,139],"Paclitaxel","Eribulin",{"nctId":202,"briefTitle":203,"status":165,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":210},"NCT00464646","Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer",[47],"2009-12","2014-05","2007-05",105,[15],[211,139,188,160,186],"Epirubicin",{"nctId":213,"briefTitle":214,"status":165,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":221},"NCT01008150","Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and\u002For Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer",[47],"2015-09","2016-11-25","2010-10",141,[15],[199,160,222,158,139],"Neratinib",{"trials":224,"activeCount":57},[225,240,251,261,271,283,293,306,317,329,343],{"nctId":226,"briefTitle":227,"status":151,"phases":228,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":234},"NCT00408408","Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery",[48],"2011-03","2018-03","2006-11",1206,[15],[235,236,173,237,238,239],"bevacizumab","capecitabine","docetaxel","doxorubicin hydrochloride","gemcitabine hydrochloride",{"nctId":241,"briefTitle":242,"status":165,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":248},"NCT00887536","A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",[48],"2018-02","2009-05",1613,[15],[235,237,249,173,250],"doxorubicin","pegfilgrastim",{"nctId":252,"briefTitle":253,"status":151,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":260},"NCT01547741","Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer",[48],"2022-05","2023-11","2012-04",1871,[15],[158,139,188,199],{"nctId":262,"briefTitle":263,"status":165,"phases":264,"completion":265,"start":266,"conditions":267,"interventions":268},"NCT00002967","Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer",[48],"2006-03","1997-05",[15],[173,238,269,270],"octreotide pamoate","tamoxifen citrate",{"nctId":272,"briefTitle":273,"status":165,"phases":274,"primaryCompletion":193,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":279},"NCT00087178","Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer",[48],"2016-05","2004-05",2722,[15],[173,280,281,282],"adriamycin","epirubicin","fluorouracil",{"nctId":284,"briefTitle":285,"status":165,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT00003782","Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes",[48],"2008-12","2012-12","1999-03",5351,[15],[173,237,249],{"nctId":294,"briefTitle":295,"status":296,"phases":297,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":303},"NCT00625898","BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","TERMINATED",[48],"2013-06","2014-07","2008-04",3509,[15],[188,160,304,186,305,211,139],"Carboplatin","5-Fluorouracil",{"nctId":307,"briefTitle":308,"status":165,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":315},"NCT00093795","Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer",[48],"2012-03","2016-06","2004-10",4894,[15],[139,188,316,199,158],"Gemcitabine",{"nctId":318,"briefTitle":319,"status":165,"phases":320,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":326},"NCT00004067","Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2",[48],"2005-03","2019-11","2000-02",2130,[15],[327,280,173,328],"herceptin","taxol",{"nctId":330,"briefTitle":331,"status":151,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT00486668","A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer",[48],"2012-06","2017-03","2007-07",529,[338],"Invasive Breast Cancer",[249,173,340,341,342],"paclitaxel","trastuzumab","lapatinib",{"nctId":344,"briefTitle":345,"status":165,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT00002707","Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed",[48],"2002-06","2010-02","1995-12",2411,[15],[139,188,158,353],"Tamoxifen",{"trials":355,"activeCount":57},[],{"trials":357,"activeCount":57},[],{"intervention":158,"totalTrials":359,"cells":360},10,{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":383,"PHASE4":409,"NA":411},{"trials":362,"activeCount":57},[],{"trials":364,"activeCount":57},[],{"trials":366,"activeCount":57},[367,371,375,379],{"nctId":149,"briefTitle":150,"status":151,"phases":368,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":369,"interventions":370},[47],[25],[158,139,159,160,161],{"nctId":177,"briefTitle":178,"status":165,"phases":372,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":373,"interventions":374},[47],[15],[186,158,139,187,188],{"nctId":190,"briefTitle":191,"status":165,"phases":376,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":377,"interventions":378},[47],[15,25],[199,200,158,139],{"nctId":213,"briefTitle":214,"status":165,"phases":380,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":381,"interventions":382},[47],[15],[199,160,222,158,139],{"trials":384,"activeCount":57},[385,389,393,397,401,405],{"nctId":241,"briefTitle":242,"status":165,"phases":386,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":387,"interventions":388},[48],[15],[235,237,249,173,250],{"nctId":252,"briefTitle":253,"status":151,"phases":390,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":391,"interventions":392},[48],[15],[158,139,188,199],{"nctId":284,"briefTitle":285,"status":165,"phases":394,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":395,"interventions":396},[48],[15],[173,237,249],{"nctId":307,"briefTitle":308,"status":165,"phases":398,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":399,"interventions":400},[48],[15],[139,188,316,199,158],{"nctId":330,"briefTitle":331,"status":151,"phases":402,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":403,"interventions":404},[48],[338],[249,173,340,341,342],{"nctId":344,"briefTitle":345,"status":165,"phases":406,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":407,"interventions":408},[48],[15],[139,188,158,353],{"trials":410,"activeCount":57},[],{"trials":412,"activeCount":57},[],{"intervention":188,"totalTrials":414,"cells":415},9,{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":430,"PHASE4":460,"NA":462},{"trials":417,"activeCount":57},[],{"trials":419,"activeCount":57},[],{"trials":421,"activeCount":57},[422,426],{"nctId":177,"briefTitle":178,"status":165,"phases":423,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":424,"interventions":425},[47],[15],[186,158,139,187,188],{"nctId":202,"briefTitle":203,"status":165,"phases":427,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":428,"interventions":429},[47],[15],[211,139,188,160,186],{"trials":431,"activeCount":57},[432,436,440,444,448,452,456],{"nctId":226,"briefTitle":227,"status":151,"phases":433,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":434,"interventions":435},[48],[15],[235,236,173,237,238,239],{"nctId":241,"briefTitle":242,"status":165,"phases":437,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":438,"interventions":439},[48],[15],[235,237,249,173,250],{"nctId":252,"briefTitle":253,"status":151,"phases":441,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":442,"interventions":443},[48],[15],[158,139,188,199],{"nctId":284,"briefTitle":285,"status":165,"phases":445,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":446,"interventions":447},[48],[15],[173,237,249],{"nctId":294,"briefTitle":295,"status":296,"phases":449,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":450,"interventions":451},[48],[15],[188,160,304,186,305,211,139],{"nctId":307,"briefTitle":308,"status":165,"phases":453,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":454,"interventions":455},[48],[15],[139,188,316,199,158],{"nctId":344,"briefTitle":345,"status":165,"phases":457,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":458,"interventions":459},[48],[15],[139,188,158,353],{"trials":461,"activeCount":57},[],{"trials":463,"activeCount":57},[],{"intervention":186,"totalTrials":465,"cells":466},7,{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":501,"PHASE4":515,"NA":517},{"trials":468,"activeCount":57},[],{"trials":470,"activeCount":57},[],{"trials":472,"activeCount":57},[473,477,488,492],{"nctId":177,"briefTitle":178,"status":165,"phases":474,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":475,"interventions":476},[47],[15],[186,158,139,187,188],{"nctId":478,"briefTitle":479,"status":296,"phases":480,"primaryCompletion":481,"completion":482,"start":265,"enrollment":465,"conditions":483,"interventions":485},"NCT00314353","Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon",[47],"2008-05","2010-06",[484],"Colorectal Neoplasms",[186,486,187,487],"Oxaliplatin","Irinotecan",{"nctId":202,"briefTitle":203,"status":165,"phases":489,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":490,"interventions":491},[47],[15],[211,139,188,160,186],{"nctId":493,"briefTitle":494,"status":165,"phases":495,"primaryCompletion":181,"completion":288,"start":265,"enrollment":496,"conditions":497,"interventions":498},"NCT00321828","Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery",[47],90,[18],[235,282,499,500],"leucovorin","oxaliplatin",{"trials":502,"activeCount":57},[503,507,511],{"nctId":226,"briefTitle":227,"status":151,"phases":504,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":505,"interventions":506},[48],[15],[235,236,173,237,238,239],{"nctId":241,"briefTitle":242,"status":165,"phases":508,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":509,"interventions":510},[48],[15],[235,237,249,173,250],{"nctId":294,"briefTitle":295,"status":296,"phases":512,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":513,"interventions":514},[48],[15],[188,160,304,186,305,211,139],{"trials":516,"activeCount":57},[],{"trials":518,"activeCount":57},[],{"intervention":282,"totalTrials":520,"cells":521},6,{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":532,"PHASE4":581,"NA":583},{"trials":523,"activeCount":57},[],{"trials":525,"activeCount":57},[],{"trials":527,"activeCount":57},[528],{"nctId":493,"briefTitle":494,"status":165,"phases":529,"primaryCompletion":181,"completion":288,"start":265,"enrollment":496,"conditions":530,"interventions":531},[47],[18],[235,282,499,500],{"trials":533,"activeCount":57},[534,545,554,558,570],{"nctId":535,"briefTitle":536,"status":165,"phases":537,"primaryCompletion":169,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":542},"NCT00425152","Fluorouracil and Leucovorin and\u002For Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer",[48],"2004-04","1989-07",2151,[18],[282,543,544],"leucovorin calcium","levamisole hydrochloride",{"nctId":546,"briefTitle":547,"status":151,"phases":548,"primaryCompletion":549,"completion":275,"start":550,"enrollment":551,"conditions":552,"interventions":553},"NCT00058474","Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer",[48],"2013-08","2004-07",1608,[18],[236,282,500],{"nctId":272,"briefTitle":273,"status":165,"phases":555,"primaryCompletion":193,"completion":275,"start":276,"enrollment":277,"conditions":556,"interventions":557},[48],[15],[173,280,281,282],{"nctId":559,"briefTitle":560,"status":165,"phases":561,"completion":562,"start":563,"conditions":564,"interventions":565},"NCT00427570","Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery",[48],"2006-05","1977-09",[18],[566,567,282,568,569],"BCG vaccine","biological therapy","semustine","vincristine sulfate",{"nctId":571,"briefTitle":572,"status":165,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":579},"NCT00427310","Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery",[48],"1989-09","2001-02","1984-03",1158,[18],[282,580],"sodium heparin",{"trials":582,"activeCount":57},[],{"trials":584,"activeCount":57},[],{"intervention":500,"totalTrials":520,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":604,"PHASE3":626,"PHASE4":642,"NA":644},{"trials":588,"activeCount":57},[],{"trials":590,"activeCount":57},[591],{"nctId":592,"briefTitle":593,"status":151,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":600},"NCT03626922","Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients",[46],"2021-10-31","2022-11","2019-05-15",33,[21],[601,602,486,603],"Pembrolizumab","Pemetrexed","Dexamethasone",{"trials":605,"activeCount":57},[606,610,614],{"nctId":478,"briefTitle":479,"status":296,"phases":607,"primaryCompletion":481,"completion":482,"start":265,"enrollment":465,"conditions":608,"interventions":609},[47],[484],[186,486,187,487],{"nctId":493,"briefTitle":494,"status":165,"phases":611,"primaryCompletion":181,"completion":288,"start":265,"enrollment":496,"conditions":612,"interventions":613},[47],[18],[235,282,499,500],{"nctId":615,"briefTitle":616,"status":165,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT00803647","A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver",[47],"2013-07","2014-11","2010-01",20,[21],[624,625,500,499],"cetuximab","5-FU",{"trials":627,"activeCount":57},[628,632],{"nctId":546,"briefTitle":547,"status":151,"phases":629,"primaryCompletion":549,"completion":275,"start":550,"enrollment":551,"conditions":630,"interventions":631},[48],[18],[236,282,500],{"nctId":633,"briefTitle":634,"status":296,"phases":635,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":640},"NCT00268463","Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and\u002For Ablation for Liver Metastases Due to Colorectal Cancer",[48],"2008-06","2006-01",22,[18,30],[236,641,500],"floxuridine",{"trials":643,"activeCount":57},[],{"trials":645,"activeCount":57},[],{"intervention":236,"totalTrials":647,"cells":648},5,{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":663,"PHASE4":677,"NA":679},{"trials":650,"activeCount":57},[],{"trials":652,"activeCount":57},[],{"trials":654,"activeCount":57},[655,659],{"nctId":177,"briefTitle":178,"status":165,"phases":656,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":657,"interventions":658},[47],[15],[186,158,139,187,188],{"nctId":478,"briefTitle":479,"status":296,"phases":660,"primaryCompletion":481,"completion":482,"start":265,"enrollment":465,"conditions":661,"interventions":662},[47],[484],[186,486,187,487],{"trials":664,"activeCount":57},[665,669,673],{"nctId":226,"briefTitle":227,"status":151,"phases":666,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":667,"interventions":668},[48],[15],[235,236,173,237,238,239],{"nctId":546,"briefTitle":547,"status":151,"phases":670,"primaryCompletion":549,"completion":275,"start":550,"enrollment":551,"conditions":671,"interventions":672},[48],[18],[236,282,500],{"nctId":633,"briefTitle":634,"status":296,"phases":674,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":675,"interventions":676},[48],[18,30],[236,641,500],{"trials":678,"activeCount":57},[],{"trials":680,"activeCount":57},[],{"intervention":353,"totalTrials":8,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":720,"NA":722},{"trials":684,"activeCount":57},[],{"trials":686,"activeCount":57},[],{"trials":688,"activeCount":57},[],{"trials":690,"activeCount":57},[691,705,716],{"nctId":692,"briefTitle":693,"status":165,"phases":694,"completion":695,"start":696,"conditions":697,"interventions":703},"NCT00000529","Tamoxifen Study",[48],"1995-11","1992-05",[698,699,700,701,702],"Cardiovascular Diseases","Coronary Disease","Heart Diseases","Hypertension","Myocardial Ischemia",[704],"tamoxifen",{"nctId":706,"briefTitle":707,"status":165,"phases":708,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":714},"NCT00003906","Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women",[48],"2005-12","2012-08","1999-05",19747,[15],[715,353],"Raloxifene",{"nctId":344,"briefTitle":345,"status":165,"phases":717,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":718,"interventions":719},[48],[15],[139,188,158,353],{"trials":721,"activeCount":57},[],{"trials":723,"activeCount":57},[],{"intervention":280,"totalTrials":8,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":736,"PHASE4":746,"NA":748},{"trials":727,"activeCount":57},[],{"trials":729,"activeCount":57},[],{"trials":731,"activeCount":57},[732],{"nctId":163,"briefTitle":164,"status":165,"phases":733,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":734,"interventions":735},[47],[15],[173,174,175],{"trials":737,"activeCount":57},[738,742],{"nctId":272,"briefTitle":273,"status":165,"phases":739,"primaryCompletion":193,"completion":275,"start":276,"enrollment":277,"conditions":740,"interventions":741},[48],[15],[173,280,281,282],{"nctId":318,"briefTitle":319,"status":165,"phases":743,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":744,"interventions":745},[48],[15],[327,280,173,328],{"trials":747,"activeCount":57},[],{"trials":749,"activeCount":57},[],{"intervention":751,"totalTrials":8,"cells":752},"Letrozole",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":784,"PHASE4":795,"NA":797},{"trials":754,"activeCount":57},[],{"trials":756,"activeCount":57},[],{"trials":758,"activeCount":57},[759,771],{"nctId":760,"briefTitle":761,"status":165,"phases":762,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":768},"NCT03628066","Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer",[47],"2020-11-30","2021-01-30","2018-10-22",24,[15],[751,769,770],"Palbociclib","Goserelin",{"nctId":772,"briefTitle":773,"status":165,"phases":774,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":782},"NCT02296801","A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer",[47],"2018-07","2019-03","2015-01",307,[15,780,781],"Breast Carcinoma","Breast Tumors",[751,783],"palbociclib",{"trials":785,"activeCount":57},[786],{"nctId":787,"briefTitle":788,"status":151,"phases":789,"primaryCompletion":790,"completion":791,"start":182,"enrollment":792,"conditions":793,"interventions":794},"NCT00382070","Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer",[48],"2016-08-25","2025-04",3966,[15],[751],{"trials":796,"activeCount":57},[],{"trials":798,"activeCount":57},[],{"intervention":211,"totalTrials":8,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":811,"PHASE4":821,"NA":823},{"trials":802,"activeCount":57},[],{"trials":804,"activeCount":57},[],{"trials":806,"activeCount":57},[807],{"nctId":202,"briefTitle":203,"status":165,"phases":808,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":809,"interventions":810},[47],[15],[211,139,188,160,186],{"trials":812,"activeCount":57},[813,817],{"nctId":272,"briefTitle":273,"status":165,"phases":814,"primaryCompletion":193,"completion":275,"start":276,"enrollment":277,"conditions":815,"interventions":816},[48],[15],[173,280,281,282],{"nctId":294,"briefTitle":295,"status":296,"phases":818,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":819,"interventions":820},[48],[15],[188,160,304,186,305,211,139],{"trials":822,"activeCount":57},[],{"trials":824,"activeCount":57},[],{"intervention":543,"totalTrials":26,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":850,"NA":852},{"trials":828,"activeCount":57},[],{"trials":830,"activeCount":57},[],{"trials":832,"activeCount":57},[],{"trials":834,"activeCount":57},[835,839],{"nctId":535,"briefTitle":536,"status":165,"phases":836,"primaryCompletion":169,"completion":538,"start":539,"enrollment":540,"conditions":837,"interventions":838},[48],[18],[282,543,544],{"nctId":840,"briefTitle":841,"status":165,"phases":842,"primaryCompletion":562,"completion":843,"start":844,"enrollment":551,"conditions":845,"interventions":846},"NCT00378716","Combination Chemotherapy in Treating Patients With Resected Colon Cancer",[48],"2009-04","1997-02",[18],[847,543,848,849],"5-fluorouracil","tegafur","uracil",{"trials":851,"activeCount":57},[],{"trials":853,"activeCount":57},[],{"intervention":238,"totalTrials":26,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":872,"NA":874},{"trials":857,"activeCount":57},[],{"trials":859,"activeCount":57},[],{"trials":861,"activeCount":57},[],{"trials":863,"activeCount":57},[864,868],{"nctId":226,"briefTitle":227,"status":151,"phases":865,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":866,"interventions":867},[48],[15],[235,236,173,237,238,239],{"nctId":262,"briefTitle":263,"status":165,"phases":869,"completion":265,"start":266,"conditions":870,"interventions":871},[48],[15],[173,238,269,270],{"trials":873,"activeCount":57},[],{"trials":875,"activeCount":57},[],{"intervention":847,"totalTrials":26,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":894,"NA":896},{"trials":879,"activeCount":57},[],{"trials":881,"activeCount":57},[],{"trials":883,"activeCount":57},[],{"trials":885,"activeCount":57},[886,890],{"nctId":840,"briefTitle":841,"status":165,"phases":887,"primaryCompletion":562,"completion":843,"start":844,"enrollment":551,"conditions":888,"interventions":889},[48],[18],[847,543,848,849],{"nctId":294,"briefTitle":295,"status":296,"phases":891,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":892,"interventions":893},[48],[15],[188,160,304,186,305,211,139],{"trials":895,"activeCount":57},[],{"trials":897,"activeCount":57},[],{"intervention":270,"totalTrials":26,"cells":899},{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":922,"NA":924},{"trials":901,"activeCount":57},[],{"trials":903,"activeCount":57},[],{"trials":905,"activeCount":57},[],{"trials":907,"activeCount":57},[908,912],{"nctId":262,"briefTitle":263,"status":165,"phases":909,"completion":265,"start":266,"conditions":910,"interventions":911},[48],[15],[173,238,269,270],{"nctId":913,"briefTitle":914,"status":165,"phases":915,"primaryCompletion":916,"completion":275,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT00053898","Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy",[48],"2015-03","2003-01",3104,[15],[921,270],"anastrozole",{"trials":923,"activeCount":57},[],{"trials":925,"activeCount":57},[],{"intervention":544,"totalTrials":53,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":940,"NA":942},{"trials":929,"activeCount":57},[],{"trials":931,"activeCount":57},[],{"trials":933,"activeCount":57},[],{"trials":935,"activeCount":57},[936],{"nctId":535,"briefTitle":536,"status":165,"phases":937,"primaryCompletion":169,"completion":538,"start":539,"enrollment":540,"conditions":938,"interventions":939},[48],[18],[282,543,544],{"trials":941,"activeCount":57},[],{"trials":943,"activeCount":57},[],{"intervention":239,"totalTrials":53,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":958,"NA":960},{"trials":947,"activeCount":57},[],{"trials":949,"activeCount":57},[],{"trials":951,"activeCount":57},[],{"trials":953,"activeCount":57},[954],{"nctId":226,"briefTitle":227,"status":151,"phases":955,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":956,"interventions":957},[48],[15],[235,236,173,237,238,239],{"trials":959,"activeCount":57},[],{"trials":961,"activeCount":57},[],{"intervention":250,"totalTrials":53,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":970,"PHASE4":976,"NA":978},{"trials":965,"activeCount":57},[],{"trials":967,"activeCount":57},[],{"trials":969,"activeCount":57},[],{"trials":971,"activeCount":57},[972],{"nctId":241,"briefTitle":242,"status":165,"phases":973,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":974,"interventions":975},[48],[15],[235,237,249,173,250],{"trials":977,"activeCount":57},[],{"trials":979,"activeCount":57},[],{"intervention":981,"totalTrials":53,"cells":982},"exemestane",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":1001,"NA":1003},{"trials":984,"activeCount":57},[],{"trials":986,"activeCount":57},[],{"trials":988,"activeCount":57},[],{"trials":990,"activeCount":57},[991],{"nctId":992,"briefTitle":993,"status":165,"phases":994,"primaryCompletion":995,"completion":996,"start":997,"enrollment":998,"conditions":999,"interventions":1000},"NCT00016432","Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen",[48],"2003-10","2011-02","2001-05",1598,[15],[981],{"trials":1002,"activeCount":57},[],{"trials":1004,"activeCount":57},[],{"intervention":848,"totalTrials":53,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1019,"NA":1021},{"trials":1008,"activeCount":57},[],{"trials":1010,"activeCount":57},[],{"trials":1012,"activeCount":57},[],{"trials":1014,"activeCount":57},[1015],{"nctId":840,"briefTitle":841,"status":165,"phases":1016,"primaryCompletion":562,"completion":843,"start":844,"enrollment":551,"conditions":1017,"interventions":1018},[48],[18],[847,543,848,849],{"trials":1020,"activeCount":57},[],{"trials":1022,"activeCount":57},[],{"intervention":849,"totalTrials":53,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":57},[],{"trials":1028,"activeCount":57},[],{"trials":1030,"activeCount":57},[],{"trials":1032,"activeCount":57},[1033],{"nctId":840,"briefTitle":841,"status":165,"phases":1034,"primaryCompletion":562,"completion":843,"start":844,"enrollment":551,"conditions":1035,"interventions":1036},[48],[18],[847,543,848,849],{"trials":1038,"activeCount":57},[],{"trials":1040,"activeCount":57},[],{"intervention":269,"totalTrials":53,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":57},[],{"trials":1046,"activeCount":57},[],{"trials":1048,"activeCount":57},[],{"trials":1050,"activeCount":57},[1051],{"nctId":262,"briefTitle":263,"status":165,"phases":1052,"completion":265,"start":266,"conditions":1053,"interventions":1054},[48],[15],[173,238,269,270],{"trials":1056,"activeCount":57},[],{"trials":1058,"activeCount":57},[],{"intervention":566,"totalTrials":53,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1073,"NA":1075},{"trials":1062,"activeCount":57},[],{"trials":1064,"activeCount":57},[],{"trials":1066,"activeCount":57},[],{"trials":1068,"activeCount":57},[1069],{"nctId":559,"briefTitle":560,"status":165,"phases":1070,"completion":562,"start":563,"conditions":1071,"interventions":1072},[48],[18],[566,567,282,568,569],{"trials":1074,"activeCount":57},[],{"trials":1076,"activeCount":57},[],{"intervention":567,"totalTrials":53,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":57},[],{"trials":1082,"activeCount":57},[],{"trials":1084,"activeCount":57},[],{"trials":1086,"activeCount":57},[1087],{"nctId":559,"briefTitle":560,"status":165,"phases":1088,"completion":562,"start":563,"conditions":1089,"interventions":1090},[48],[18],[566,567,282,568,569],{"trials":1092,"activeCount":57},[],{"trials":1094,"activeCount":57},[],{"intervention":568,"totalTrials":53,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":57},[],{"trials":1100,"activeCount":57},[],{"trials":1102,"activeCount":57},[],{"trials":1104,"activeCount":57},[1105],{"nctId":559,"briefTitle":560,"status":165,"phases":1106,"completion":562,"start":563,"conditions":1107,"interventions":1108},[48],[18],[566,567,282,568,569],{"trials":1110,"activeCount":57},[],{"trials":1112,"activeCount":57},[],{"intervention":569,"totalTrials":53,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1121,"PHASE4":1127,"NA":1129},{"trials":1116,"activeCount":57},[],{"trials":1118,"activeCount":57},[],{"trials":1120,"activeCount":57},[],{"trials":1122,"activeCount":57},[1123],{"nctId":559,"briefTitle":560,"status":165,"phases":1124,"completion":562,"start":563,"conditions":1125,"interventions":1126},[48],[18],[566,567,282,568,569],{"trials":1128,"activeCount":57},[],{"trials":1130,"activeCount":57},[],{"intervention":641,"totalTrials":53,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1145,"NA":1147},{"trials":1134,"activeCount":57},[],{"trials":1136,"activeCount":57},[],{"trials":1138,"activeCount":57},[],{"trials":1140,"activeCount":57},[1141],{"nctId":633,"briefTitle":634,"status":296,"phases":1142,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":1143,"interventions":1144},[48],[18,30],[236,641,500],{"trials":1146,"activeCount":57},[],{"trials":1148,"activeCount":57},[],{"intervention":1150,"totalTrials":53,"cells":1151},"rosuvastatin",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1171,"NA":1173},{"trials":1153,"activeCount":57},[],{"trials":1155,"activeCount":57},[],{"trials":1157,"activeCount":57},[],{"trials":1159,"activeCount":57},[1160],{"nctId":1161,"briefTitle":1162,"status":296,"phases":1163,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1170},"NCT01011478","Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery",[48],"2014-12","2015-02","2010-03",406,[18,1169],"Precancerous Condition",[1150],{"trials":1172,"activeCount":57},[],{"trials":1174,"activeCount":57},[],{"intervention":1176,"totalTrials":53,"cells":1177},"Regorafenib",{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1195,"NA":1197},{"trials":1179,"activeCount":57},[],{"trials":1181,"activeCount":57},[],{"trials":1183,"activeCount":57},[],{"trials":1185,"activeCount":57},[1186],{"nctId":1187,"briefTitle":1188,"status":296,"phases":1189,"primaryCompletion":1190,"completion":1190,"start":311,"enrollment":1191,"conditions":1192,"interventions":1194},"NCT02664077","A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer",[48],"2019-10",34,[1193],"Stage III (IIIB or IIIC) Colon Cancer",[1176],{"trials":1196,"activeCount":57},[],{"trials":1198,"activeCount":57},[],{"intervention":921,"totalTrials":53,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":57},[],{"trials":1204,"activeCount":57},[],{"trials":1206,"activeCount":57},[],{"trials":1208,"activeCount":57},[1209],{"nctId":913,"briefTitle":914,"status":165,"phases":1210,"primaryCompletion":916,"completion":275,"start":917,"enrollment":918,"conditions":1211,"interventions":1212},[48],[15],[921,270],{"trials":1214,"activeCount":57},[],{"trials":1216,"activeCount":57},[],{"intervention":580,"totalTrials":53,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1231,"NA":1233},{"trials":1220,"activeCount":57},[],{"trials":1222,"activeCount":57},[],{"trials":1224,"activeCount":57},[],{"trials":1226,"activeCount":57},[1227],{"nctId":571,"briefTitle":572,"status":165,"phases":1228,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":1229,"interventions":1230},[48],[18],[282,580],{"trials":1232,"activeCount":57},[],{"trials":1234,"activeCount":57},[],{"intervention":304,"totalTrials":53,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":57},[],{"trials":1240,"activeCount":57},[],{"trials":1242,"activeCount":57},[],{"trials":1244,"activeCount":57},[1245],{"nctId":294,"briefTitle":295,"status":296,"phases":1246,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":1247,"interventions":1248},[48],[15],[188,160,304,186,305,211,139],{"trials":1250,"activeCount":57},[],{"trials":1252,"activeCount":57},[],{"intervention":316,"totalTrials":53,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":57},[],{"trials":1258,"activeCount":57},[],{"trials":1260,"activeCount":57},[],{"trials":1262,"activeCount":57},[1263],{"nctId":307,"briefTitle":308,"status":165,"phases":1264,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":1265,"interventions":1266},[48],[15],[139,188,316,199,158],{"trials":1268,"activeCount":57},[],{"trials":1270,"activeCount":57},[],{"intervention":327,"totalTrials":53,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1285,"NA":1287},{"trials":1274,"activeCount":57},[],{"trials":1276,"activeCount":57},[],{"trials":1278,"activeCount":57},[],{"trials":1280,"activeCount":57},[1281],{"nctId":318,"briefTitle":319,"status":165,"phases":1282,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":1283,"interventions":1284},[48],[15],[327,280,173,328],{"trials":1286,"activeCount":57},[],{"trials":1288,"activeCount":57},[],{"intervention":328,"totalTrials":53,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1303,"NA":1305},{"trials":1292,"activeCount":57},[],{"trials":1294,"activeCount":57},[],{"trials":1296,"activeCount":57},[],{"trials":1298,"activeCount":57},[1299],{"nctId":318,"briefTitle":319,"status":165,"phases":1300,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":1301,"interventions":1302},[48],[15],[327,280,173,328],{"trials":1304,"activeCount":57},[],{"trials":1306,"activeCount":57},[],{"intervention":1308,"totalTrials":53,"cells":1309},"Celecoxib",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1326,"NA":1328},{"trials":1311,"activeCount":57},[],{"trials":1313,"activeCount":57},[],{"trials":1315,"activeCount":57},[],{"trials":1317,"activeCount":57},[1318],{"nctId":1319,"briefTitle":1320,"status":296,"phases":1321,"primaryCompletion":1322,"completion":1322,"start":550,"enrollment":1323,"conditions":1324,"interventions":1325},"NCT00087256","Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer",[48],"2006-04",18,[18],[1308],{"trials":1327,"activeCount":57},[],{"trials":1329,"activeCount":57},[],{"intervention":342,"totalTrials":53,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1344,"NA":1346},{"trials":1333,"activeCount":57},[],{"trials":1335,"activeCount":57},[],{"trials":1337,"activeCount":57},[],{"trials":1339,"activeCount":57},[1340],{"nctId":330,"briefTitle":331,"status":151,"phases":1341,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":1342,"interventions":1343},[48],[338],[249,173,340,341,342],{"trials":1345,"activeCount":57},[],{"trials":1347,"activeCount":57},[],{"intervention":715,"totalTrials":53,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":57},[],{"trials":1353,"activeCount":57},[],{"trials":1355,"activeCount":57},[],{"trials":1357,"activeCount":57},[1358],{"nctId":706,"briefTitle":707,"status":165,"phases":1359,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":1360,"interventions":1361},[48],[15],[715,353],{"trials":1363,"activeCount":57},[],{"trials":1365,"activeCount":57},[],{"intervention":1367,"totalTrials":53,"cells":1368},"clodronate",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1385,"NA":1387},{"trials":1370,"activeCount":57},[],{"trials":1372,"activeCount":57},[],{"trials":1374,"activeCount":57},[],{"trials":1376,"activeCount":57},[1377],{"nctId":1378,"briefTitle":1379,"status":165,"phases":1380,"primaryCompletion":229,"completion":288,"start":1381,"enrollment":1382,"conditions":1383,"interventions":1384},"NCT00009945","Clodronate With or Without Chemotherapy and\u002For Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer",[48],"2001-01",3323,[15],[1367],{"trials":1386,"activeCount":57},[],{"trials":1388,"activeCount":57},[],{"intervention":222,"totalTrials":647,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1403,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1392,"activeCount":57},[],{"trials":1394,"activeCount":57},[1395],{"nctId":1396,"briefTitle":1397,"status":165,"phases":1398,"primaryCompletion":710,"completion":193,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1402},"NCT01423123","Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer",[46],"2011-05",21,[15],[199,341,222],{"trials":1404,"activeCount":57},[1405,1416,1426,1435],{"nctId":1406,"briefTitle":1407,"status":165,"phases":1408,"primaryCompletion":1409,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1414},"NCT02236000","A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer",[46,47],"2020-12","2021-08","2014-08",49,[15],[222,1415],"T-DM1",{"nctId":1417,"briefTitle":1418,"status":151,"phases":1419,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":16,"conditions":1423,"interventions":1424},"NCT03457896","Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS\u002FNRAS\u002FBRAF\u002FPIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",[47],"2021-09-30","2022-09-30","2018-05-18",[21],[160,1425,222],"Cetuximab",{"nctId":1427,"briefTitle":1428,"status":1429,"phases":1430,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":57,"conditions":1433,"interventions":1434},"NCT01960023","Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer","WITHDRAWN",[46,47],"2016-07-13","2013-10",[18],[1425,222],{"nctId":213,"briefTitle":214,"status":165,"phases":1436,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":1437,"interventions":1438},[47],[15],[199,160,222,158,139],{"trials":1440,"activeCount":57},[],{"trials":1442,"activeCount":57},[],{"trials":1444,"activeCount":57},[],{"intervention":1425,"totalTrials":8,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1448,"activeCount":57},[],{"trials":1450,"activeCount":57},[],{"trials":1452,"activeCount":57},[1453,1457,1461],{"nctId":1417,"briefTitle":1418,"status":151,"phases":1454,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":16,"conditions":1455,"interventions":1456},[47],[21],[160,1425,222],{"nctId":1427,"briefTitle":1428,"status":1429,"phases":1458,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":57,"conditions":1459,"interventions":1460},[46,47],[18],[1425,222],{"nctId":615,"briefTitle":616,"status":165,"phases":1462,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":1463,"interventions":1464},[47],[21],[624,625,500,499],{"trials":1466,"activeCount":57},[],{"trials":1468,"activeCount":57},[],{"trials":1470,"activeCount":57},[],{"intervention":769,"totalTrials":26,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1487,"PHASE4":1489,"NA":1491},{"trials":1474,"activeCount":57},[],{"trials":1476,"activeCount":57},[],{"trials":1478,"activeCount":57},[1479,1483],{"nctId":760,"briefTitle":761,"status":165,"phases":1480,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":1481,"interventions":1482},[47],[15],[751,769,770],{"nctId":772,"briefTitle":773,"status":165,"phases":1484,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":1485,"interventions":1486},[47],[15,780,781],[751,783],{"trials":1488,"activeCount":57},[],{"trials":1490,"activeCount":57},[],{"trials":1492,"activeCount":57},[],{"intervention":1494,"totalTrials":26,"cells":1495},"durvalumab",{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1500,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1497,"activeCount":57},[],{"trials":1499,"activeCount":57},[],{"trials":1501,"activeCount":57},[1502,1513],{"nctId":1503,"briefTitle":1504,"status":165,"phases":1505,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":598,"conditions":1509,"interventions":1511},"NCT03007407","Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy",[47],"2019-04-18","2019-08-09","2017-07-31",[1510],"Colorectal Cancer Metastatic",[1494,1512],"Tremelimumab",{"nctId":1514,"briefTitle":1515,"status":165,"phases":1516,"primaryCompletion":1517,"completion":1518,"start":154,"enrollment":183,"conditions":1519,"interventions":1520},"NCT03102047","Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer",[47],"2021-02-22","2021-12-30",[32],[1494],{"trials":1522,"activeCount":57},[],{"trials":1524,"activeCount":57},[],{"trials":1526,"activeCount":57},[],{"intervention":499,"totalTrials":26,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1530,"activeCount":57},[],{"trials":1532,"activeCount":57},[],{"trials":1534,"activeCount":57},[1535,1539],{"nctId":493,"briefTitle":494,"status":165,"phases":1536,"primaryCompletion":181,"completion":288,"start":265,"enrollment":496,"conditions":1537,"interventions":1538},[47],[18],[235,282,499,500],{"nctId":615,"briefTitle":616,"status":165,"phases":1540,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":1541,"interventions":1542},[47],[21],[624,625,500,499],{"trials":1544,"activeCount":57},[],{"trials":1546,"activeCount":57},[],{"trials":1548,"activeCount":57},[],{"intervention":625,"totalTrials":26,"cells":1550},{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1571,"PHASE4":1573,"NA":1575},{"trials":1552,"activeCount":57},[],{"trials":1554,"activeCount":57},[],{"trials":1556,"activeCount":57},[1557,1567],{"nctId":1558,"briefTitle":1559,"status":1429,"phases":1560,"primaryCompletion":275,"completion":1561,"start":619,"enrollment":57,"conditions":1562,"interventions":1563},"NCT01889680","Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer",[47],"2018-05",[18,21],[625,1564,1565,1566],"LV","ziv-aflibercept","mFOLFOX6",{"nctId":615,"briefTitle":616,"status":165,"phases":1568,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":1569,"interventions":1570},[47],[21],[624,625,500,499],{"trials":1572,"activeCount":57},[],{"trials":1574,"activeCount":57},[],{"trials":1576,"activeCount":57},[],{"intervention":159,"totalTrials":53,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1589,"PHASE4":1591,"NA":1593},{"trials":1580,"activeCount":57},[],{"trials":1582,"activeCount":57},[],{"trials":1584,"activeCount":57},[1585],{"nctId":149,"briefTitle":150,"status":151,"phases":1586,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":1587,"interventions":1588},[47],[25],[158,139,159,160,161],{"trials":1590,"activeCount":57},[],{"trials":1592,"activeCount":57},[],{"trials":1594,"activeCount":57},[],{"intervention":174,"totalTrials":53,"cells":1596},{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1598,"activeCount":57},[],{"trials":1600,"activeCount":57},[],{"trials":1602,"activeCount":57},[1603],{"nctId":163,"briefTitle":164,"status":165,"phases":1604,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":1605,"interventions":1606},[47],[15],[173,174,175],{"trials":1608,"activeCount":57},[],{"trials":1610,"activeCount":57},[],{"trials":1612,"activeCount":57},[],{"intervention":770,"totalTrials":53,"cells":1614},{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1616,"activeCount":57},[],{"trials":1618,"activeCount":57},[],{"trials":1620,"activeCount":57},[1621],{"nctId":760,"briefTitle":761,"status":165,"phases":1622,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":1623,"interventions":1624},[47],[15],[751,769,770],{"trials":1626,"activeCount":57},[],{"trials":1628,"activeCount":57},[],{"trials":1630,"activeCount":57},[],{"intervention":1415,"totalTrials":53,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1634,"activeCount":57},[],{"trials":1636,"activeCount":57},[],{"trials":1638,"activeCount":57},[1639],{"nctId":1406,"briefTitle":1407,"status":165,"phases":1640,"primaryCompletion":1409,"completion":1410,"start":1411,"enrollment":1412,"conditions":1641,"interventions":1642},[46,47],[15],[222,1415],{"trials":1644,"activeCount":57},[],{"trials":1646,"activeCount":57},[],{"trials":1648,"activeCount":57},[],{"intervention":1650,"totalTrials":53,"cells":1651},"ZD1839 in combination with docetaxel",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1653,"activeCount":57},[],{"trials":1655,"activeCount":57},[],{"trials":1657,"activeCount":57},[1658],{"nctId":1659,"briefTitle":1660,"status":165,"phases":1661,"completion":1662,"start":917,"enrollment":598,"conditions":1663,"interventions":1664},"NCT00052169","Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer",[47],"2006-09",[28],[1650],{"trials":1666,"activeCount":57},[],{"trials":1668,"activeCount":57},[],{"trials":1670,"activeCount":57},[],{"intervention":200,"totalTrials":53,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":57},[],{"trials":1676,"activeCount":57},[],{"trials":1678,"activeCount":57},[1679],{"nctId":190,"briefTitle":191,"status":165,"phases":1680,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":1681,"interventions":1682},[47],[15,25],[199,200,158,139],{"trials":1684,"activeCount":57},[],{"trials":1686,"activeCount":57},[],{"trials":1688,"activeCount":57},[],{"intervention":487,"totalTrials":53,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1692,"activeCount":57},[],{"trials":1694,"activeCount":57},[],{"trials":1696,"activeCount":57},[1697],{"nctId":478,"briefTitle":479,"status":296,"phases":1698,"primaryCompletion":481,"completion":482,"start":265,"enrollment":465,"conditions":1699,"interventions":1700},[47],[484],[186,486,187,487],{"trials":1702,"activeCount":57},[],{"trials":1704,"activeCount":57},[],{"trials":1706,"activeCount":57},[],{"intervention":1512,"totalTrials":53,"cells":1708},{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1719,"PHASE4":1721,"NA":1723},{"trials":1710,"activeCount":57},[],{"trials":1712,"activeCount":57},[],{"trials":1714,"activeCount":57},[1715],{"nctId":1503,"briefTitle":1504,"status":165,"phases":1716,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":598,"conditions":1717,"interventions":1718},[47],[1510],[1494,1512],{"trials":1720,"activeCount":57},[],{"trials":1722,"activeCount":57},[],{"trials":1724,"activeCount":57},[],{"intervention":1726,"totalTrials":53,"cells":1727},"Nanoparticle albumin bound paclitaxel followed by FEC",{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1732,"PHASE3":1743,"PHASE4":1745,"NA":1747},{"trials":1729,"activeCount":57},[],{"trials":1731,"activeCount":57},[],{"trials":1733,"activeCount":57},[1734],{"nctId":1735,"briefTitle":1736,"status":165,"phases":1737,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":6,"conditions":1741,"interventions":1742},"NCT00110695","Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer",[47],"2006-12","2008-07","2005-04",[28],[1726],{"trials":1744,"activeCount":57},[],{"trials":1746,"activeCount":57},[],{"trials":1748,"activeCount":57},[],{"intervention":1750,"totalTrials":53,"cells":1751},"gemcitabine, epirubicin, paclitaxel",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1753,"activeCount":57},[],{"trials":1755,"activeCount":57},[],{"trials":1757,"activeCount":57},[1758],{"nctId":1759,"briefTitle":1760,"status":165,"phases":1761,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1771},"NCT00378313","A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer",[47],"2005-11","2001-11",76,[1766,1767,1768,1769,15,1770],"Stage IIB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IV Breast Cancer","Locally Advanced",[1750],{"trials":1773,"activeCount":57},[],{"trials":1775,"activeCount":57},[],{"trials":1777,"activeCount":57},[],{"intervention":1564,"totalTrials":53,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":57},[],{"trials":1783,"activeCount":57},[],{"trials":1785,"activeCount":57},[1786],{"nctId":1558,"briefTitle":1559,"status":1429,"phases":1787,"primaryCompletion":275,"completion":1561,"start":619,"enrollment":57,"conditions":1788,"interventions":1789},[47],[18,21],[625,1564,1565,1566],{"trials":1791,"activeCount":57},[],{"trials":1793,"activeCount":57},[],{"trials":1795,"activeCount":57},[],{"intervention":1565,"totalTrials":53,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":57},[],{"trials":1801,"activeCount":57},[],{"trials":1803,"activeCount":57},[1804],{"nctId":1558,"briefTitle":1559,"status":1429,"phases":1805,"primaryCompletion":275,"completion":1561,"start":619,"enrollment":57,"conditions":1806,"interventions":1807},[47],[18,21],[625,1564,1565,1566],{"trials":1809,"activeCount":57},[],{"trials":1811,"activeCount":57},[],{"trials":1813,"activeCount":57},[],{"intervention":1566,"totalTrials":53,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":57},[],{"trials":1819,"activeCount":57},[],{"trials":1821,"activeCount":57},[1822],{"nctId":1558,"briefTitle":1559,"status":1429,"phases":1823,"primaryCompletion":275,"completion":1561,"start":619,"enrollment":57,"conditions":1824,"interventions":1825},[47],[18,21],[625,1564,1565,1566],{"trials":1827,"activeCount":57},[],{"trials":1829,"activeCount":57},[],{"trials":1831,"activeCount":57},[],{"intervention":1833,"totalTrials":53,"cells":1834},"Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1839,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1836,"activeCount":57},[],{"trials":1838,"activeCount":57},[],{"trials":1840,"activeCount":57},[1841],{"nctId":1842,"briefTitle":1843,"status":1429,"phases":1844,"completion":207,"start":1845,"enrollment":57,"conditions":1846,"interventions":1848},"NCT00346099","Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum",[47],"2006-06",[32,1847],"Neoplasm Metastasis",[1833,1849],"Panitumumab with capecitabine and radiation",{"trials":1851,"activeCount":57},[],{"trials":1853,"activeCount":57},[],{"trials":1855,"activeCount":57},[],{"intervention":1849,"totalTrials":53,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1859,"activeCount":57},[],{"trials":1861,"activeCount":57},[],{"trials":1863,"activeCount":57},[1864],{"nctId":1842,"briefTitle":1843,"status":1429,"phases":1865,"completion":207,"start":1845,"enrollment":57,"conditions":1866,"interventions":1867},[47],[32,1847],[1833,1849],{"trials":1869,"activeCount":57},[],{"trials":1871,"activeCount":57},[],{"trials":1873,"activeCount":57},[],{"intervention":1875,"totalTrials":53,"cells":1876},"Gevokizumab",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1878,"activeCount":57},[],{"trials":1880,"activeCount":57},[],{"trials":1882,"activeCount":57},[1883],{"nctId":1884,"briefTitle":1885,"status":1429,"phases":1886,"primaryCompletion":1887,"completion":1888,"start":1889,"enrollment":57,"conditions":1890,"interventions":1892},"NCT05178576","A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II\u002FIII Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy",[47],"2026-02","2027-02","2022-06-24",[1891],"Colon Cancer",[1875],{"trials":1894,"activeCount":57},[],{"trials":1896,"activeCount":57},[],{"trials":1898,"activeCount":57},[],{"intervention":601,"totalTrials":53,"cells":1900},{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1902,"activeCount":57},[],{"trials":1904,"activeCount":57},[1905],{"nctId":592,"briefTitle":593,"status":151,"phases":1906,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":1907,"interventions":1908},[46],[21],[601,602,486,603],{"trials":1910,"activeCount":57},[],{"trials":1912,"activeCount":57},[],{"trials":1914,"activeCount":57},[],{"trials":1916,"activeCount":57},[],{"intervention":602,"totalTrials":53,"cells":1918},{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1927,"PHASE3":1929,"PHASE4":1931,"NA":1933},{"trials":1920,"activeCount":57},[],{"trials":1922,"activeCount":57},[1923],{"nctId":592,"briefTitle":593,"status":151,"phases":1924,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":1925,"interventions":1926},[46],[21],[601,602,486,603],{"trials":1928,"activeCount":57},[],{"trials":1930,"activeCount":57},[],{"trials":1932,"activeCount":57},[],{"trials":1934,"activeCount":57},[],{"intervention":603,"totalTrials":53,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1938,"activeCount":57},[],{"trials":1940,"activeCount":57},[1941],{"nctId":592,"briefTitle":593,"status":151,"phases":1942,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":1943,"interventions":1944},[46],[21],[601,602,486,603],{"trials":1946,"activeCount":57},[],{"trials":1948,"activeCount":57},[],{"trials":1950,"activeCount":57},[],{"trials":1952,"activeCount":57},[],{"intervention":160,"totalTrials":12,"cells":1954},{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1963,"PHASE3":1981,"PHASE4":1991,"NA":1993},{"trials":1956,"activeCount":57},[],{"trials":1958,"activeCount":57},[1959],{"nctId":1396,"briefTitle":1397,"status":165,"phases":1960,"primaryCompletion":710,"completion":193,"start":1399,"enrollment":1400,"conditions":1961,"interventions":1962},[46],[15],[199,341,222],{"trials":1964,"activeCount":57},[1965,1969,1973,1977],{"nctId":149,"briefTitle":150,"status":151,"phases":1966,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":1967,"interventions":1968},[47],[25],[158,139,159,160,161],{"nctId":202,"briefTitle":203,"status":165,"phases":1970,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":1971,"interventions":1972},[47],[15],[211,139,188,160,186],{"nctId":1417,"briefTitle":1418,"status":151,"phases":1974,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":16,"conditions":1975,"interventions":1976},[47],[21],[160,1425,222],{"nctId":213,"briefTitle":214,"status":165,"phases":1978,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":1979,"interventions":1980},[47],[15],[199,160,222,158,139],{"trials":1982,"activeCount":57},[1983,1987],{"nctId":294,"briefTitle":295,"status":296,"phases":1984,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":1985,"interventions":1986},[48],[15],[188,160,304,186,305,211,139],{"nctId":330,"briefTitle":331,"status":151,"phases":1988,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":1989,"interventions":1990},[48],[338],[249,173,340,341,342],{"trials":1992,"activeCount":57},[],{"trials":1994,"activeCount":57},[1995],{"nctId":1996,"briefTitle":1997,"status":151,"phases":1998,"primaryCompletion":1999,"completion":2000,"start":618,"enrollment":196,"conditions":2001,"interventions":2002},"NCT01850628","NSABP Biospecimen Discovery Project",[],"2018-06","2022-02",[15],[199,341,2003],"pertuzumab",{"intervention":199,"totalTrials":465,"cells":2005},{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2014,"PHASE3":2024,"PHASE4":2038,"NA":2040},{"trials":2007,"activeCount":57},[],{"trials":2009,"activeCount":57},[2010],{"nctId":1396,"briefTitle":1397,"status":165,"phases":2011,"primaryCompletion":710,"completion":193,"start":1399,"enrollment":1400,"conditions":2012,"interventions":2013},[46],[15],[199,341,222],{"trials":2015,"activeCount":57},[2016,2020],{"nctId":190,"briefTitle":191,"status":165,"phases":2017,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":2018,"interventions":2019},[47],[15,25],[199,200,158,139],{"nctId":213,"briefTitle":214,"status":165,"phases":2021,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":2022,"interventions":2023},[47],[15],[199,160,222,158,139],{"trials":2025,"activeCount":57},[2026,2030,2034],{"nctId":252,"briefTitle":253,"status":151,"phases":2027,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":2028,"interventions":2029},[48],[15],[158,139,188,199],{"nctId":307,"briefTitle":308,"status":165,"phases":2031,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":2032,"interventions":2033},[48],[15],[139,188,316,199,158],{"nctId":330,"briefTitle":331,"status":151,"phases":2035,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":2036,"interventions":2037},[48],[338],[249,173,340,341,342],{"trials":2039,"activeCount":57},[],{"trials":2041,"activeCount":57},[2042],{"nctId":1996,"briefTitle":1997,"status":151,"phases":2043,"primaryCompletion":1999,"completion":2000,"start":618,"enrollment":196,"conditions":2044,"interventions":2045},[],[15],[199,341,2003],{"intervention":161,"totalTrials":26,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2049,"activeCount":57},[],{"trials":2051,"activeCount":57},[],{"trials":2053,"activeCount":57},[2054],{"nctId":149,"briefTitle":150,"status":151,"phases":2055,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":2056,"interventions":2057},[47],[25],[158,139,159,160,161],{"trials":2059,"activeCount":57},[],{"trials":2061,"activeCount":57},[],{"trials":2063,"activeCount":57},[2064],{"nctId":1996,"briefTitle":1997,"status":151,"phases":2065,"primaryCompletion":1999,"completion":2000,"start":618,"enrollment":196,"conditions":2066,"interventions":2067},[],[15],[199,341,2003],{"intervention":2069,"totalTrials":26,"cells":2070},"gene expression analysis",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2079,"NA":2081},{"trials":2072,"activeCount":57},[],{"trials":2074,"activeCount":57},[],{"trials":2076,"activeCount":57},[],{"trials":2078,"activeCount":57},[],{"trials":2080,"activeCount":57},[],{"trials":2082,"activeCount":57},[2083,2093],{"nctId":2084,"briefTitle":2085,"status":1429,"phases":2086,"primaryCompletion":482,"completion":482,"enrollment":57,"conditions":2087,"interventions":2088},"NCT00914043","Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45",[],[15,23],[2069,2089,2090,2091,2092],"microarray analysis","polymerase chain reaction","polymorphism analysis","reverse transcriptase-polymerase chain reaction",{"nctId":2094,"briefTitle":2095,"status":151,"phases":2096,"primaryCompletion":2097,"start":2098,"enrollment":2099,"conditions":2100,"interventions":2101},"NCT01420185","Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28",[],"2015-12","2011-10",1300,[15],[2102,2069,2089,2092],"RNA analysis",{"intervention":2089,"totalTrials":26,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2106,"activeCount":57},[],{"trials":2108,"activeCount":57},[],{"trials":2110,"activeCount":57},[],{"trials":2112,"activeCount":57},[],{"trials":2114,"activeCount":57},[],{"trials":2116,"activeCount":57},[2117,2121],{"nctId":2084,"briefTitle":2085,"status":1429,"phases":2118,"primaryCompletion":482,"completion":482,"enrollment":57,"conditions":2119,"interventions":2120},[],[15,23],[2069,2089,2090,2091,2092],{"nctId":2094,"briefTitle":2095,"status":151,"phases":2122,"primaryCompletion":2097,"start":2098,"enrollment":2099,"conditions":2123,"interventions":2124},[],[15],[2102,2069,2089,2092],{"intervention":2091,"totalTrials":26,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2128,"activeCount":57},[],{"trials":2130,"activeCount":57},[],{"trials":2132,"activeCount":57},[],{"trials":2134,"activeCount":57},[],{"trials":2136,"activeCount":57},[],{"trials":2138,"activeCount":57},[2139,2143],{"nctId":2084,"briefTitle":2085,"status":1429,"phases":2140,"primaryCompletion":482,"completion":482,"enrollment":57,"conditions":2141,"interventions":2142},[],[15,23],[2069,2089,2090,2091,2092],{"nctId":2144,"briefTitle":2145,"status":151,"phases":2146,"primaryCompletion":2097,"start":843,"enrollment":2147,"conditions":2148,"interventions":2149},"NCT00967239","Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2",[],1881,[15],[2150,2091],"DNA analysis",{"intervention":2092,"totalTrials":26,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2154,"activeCount":57},[],{"trials":2156,"activeCount":57},[],{"trials":2158,"activeCount":57},[],{"trials":2160,"activeCount":57},[],{"trials":2162,"activeCount":57},[],{"trials":2164,"activeCount":57},[2165,2169],{"nctId":2084,"briefTitle":2085,"status":1429,"phases":2166,"primaryCompletion":482,"completion":482,"enrollment":57,"conditions":2167,"interventions":2168},[],[15,23],[2069,2089,2090,2091,2092],{"nctId":2094,"briefTitle":2095,"status":151,"phases":2170,"primaryCompletion":2097,"start":2098,"enrollment":2099,"conditions":2171,"interventions":2172},[],[15],[2102,2069,2089,2092],{"intervention":2090,"totalTrials":53,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2183,"NA":2185},{"trials":2176,"activeCount":57},[],{"trials":2178,"activeCount":57},[],{"trials":2180,"activeCount":57},[],{"trials":2182,"activeCount":57},[],{"trials":2184,"activeCount":57},[],{"trials":2186,"activeCount":57},[2187],{"nctId":2084,"briefTitle":2085,"status":1429,"phases":2188,"primaryCompletion":482,"completion":482,"enrollment":57,"conditions":2189,"interventions":2190},[],[15,23],[2069,2089,2090,2091,2092],{"intervention":2102,"totalTrials":53,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2199,"PHASE4":2201,"NA":2203},{"trials":2194,"activeCount":57},[],{"trials":2196,"activeCount":57},[],{"trials":2198,"activeCount":57},[],{"trials":2200,"activeCount":57},[],{"trials":2202,"activeCount":57},[],{"trials":2204,"activeCount":57},[2205],{"nctId":2094,"briefTitle":2095,"status":151,"phases":2206,"primaryCompletion":2097,"start":2098,"enrollment":2099,"conditions":2207,"interventions":2208},[],[15],[2102,2069,2089,2092],{"intervention":2150,"totalTrials":53,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2217,"PHASE4":2219,"NA":2221},{"trials":2212,"activeCount":57},[],{"trials":2214,"activeCount":57},[],{"trials":2216,"activeCount":57},[],{"trials":2218,"activeCount":57},[],{"trials":2220,"activeCount":57},[],{"trials":2222,"activeCount":57},[2223],{"nctId":2144,"briefTitle":2145,"status":151,"phases":2224,"primaryCompletion":2097,"start":843,"enrollment":2147,"conditions":2225,"interventions":2226},[],[15],[2150,2091],{"intervention":2228,"totalTrials":53,"cells":2229},"Metformin",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2236,"PHASE4":2238,"NA":2240},{"trials":2231,"activeCount":57},[],{"trials":2233,"activeCount":57},[],{"trials":2235,"activeCount":57},[],{"trials":2237,"activeCount":57},[],{"trials":2239,"activeCount":57},[],{"trials":2241,"activeCount":57},[2242],{"nctId":2243,"briefTitle":2244,"status":151,"phases":2245,"primaryCompletion":2246,"completion":2246,"start":2247,"enrollment":2248,"conditions":2249,"interventions":2252},"NCT01286233","Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32",[],"2016-09","2011-07",394,[15,2250,23,2251],"Depression","Sleep Disorders",[2228],{"intervention":2254,"totalTrials":53,"cells":2255},"fluorescence in situ hybridization",{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2257,"activeCount":57},[],{"trials":2259,"activeCount":57},[],{"trials":2261,"activeCount":57},[],{"trials":2263,"activeCount":57},[],{"trials":2265,"activeCount":57},[],{"trials":2267,"activeCount":57},[2268],{"nctId":2269,"briefTitle":2270,"status":151,"phases":2271,"primaryCompletion":2097,"start":2272,"enrollment":2273,"conditions":2274,"interventions":2275},"NCT01424865","Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial",[],"2011-11",1874,[15],[2254]]